Page last updated: 2024-12-07

4-hydroxymidazolam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-hydroxymidazolam: metabolite of midazolam; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-hydroxymidazolam : An imidazobenzodiazepine that is midazolam which is substituted by a hydroxy group at position 4. It is the minor hydroxylated metabolite of the anesthetic, midazolam. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID124449
CHEMBL ID2074876
CHEBI ID145331
SCHEMBL ID7311167
MeSH IDM0126559

Synonyms (25)

Synonym
4-hydroxymidazolam
NCGC00165944-01
59468-85-8
ro 21-5975
8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepin-4-ol
4-oh midazolam
4-oh-mdz
CHEBI:145331
CHEMBL2074876
4h-imidazo(1,5-a)(1,4)benzodiazepin-4-ol, 8-chloro-6-(2-fluorophenyl)-1-methyl-
unii-liw2rh792r
liw2rh792r ,
4-hydroxy midazolam
SCHEMBL7311167
4-hydroxy-midazolam
ZYISITHKPKHPKG-UHFFFAOYSA-N
AKOS030242505
CS-0018035
HY-100050
(e)-8-chloro-6-(2-fluorophenyl)-1-methyl-4h-benzo[f]imidazo[1,5-a][1,4]diazepin-4-ol
BCP28138
8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo(1,5-a)(1,4)benzodiazepin-4-ol
DTXSID20974870
4-hydroxymidazolam, 1mg/ml in acetonitrile
4h-imidazo[1,5-a][1,4]benzodiazepin-4-ol, 8-chloro-6-(2-fluorophenyl)-1-methyl- (9ci, aci); 8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepin-4-ol (aci); 4-hydroxymidazolam

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"5 mg/kg) administration of MDZ, and pharmacokinetic parameters were estimated by fitting to a noncompartmental model."( Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Akiyama, TE; Cheung, C; Elizondo, G; Feigenbaum, L; Gonzalez, FJ; Granvil, CP; Krausz, KW; Yu, AM, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
drug metabolitenull
human blood serum metaboliteAny metabolite (endogenous or exogenous) found in human blood serum samples.
human urinary metaboliteAny metabolite (endogenous or exogenous) found in human urine samples.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
imidazobenzodiazepineAny organic heterotricyclic compound that is any benzodiazepine which is ortho-fused with a imidazole.
monofluorobenzenesAny member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying a single fluorine substitutent.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
organic hydroxy compoundAn organic compound having at least one hydroxy group attached to a carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID680047TP_TRANSPORTER: inhibition of Daunorubicin transepithelial transport (basal to apical)(Daunorubicin: 0.035 uM, 4-hydroxymidazolam: 50 uM) in MDR1-expressing LLC-PK1 cells2001European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Feb, Volume: 12, Issue:4
Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.85)18.7374
1990's6 (23.08)18.2507
2000's10 (38.46)29.6817
2010's8 (30.77)24.3611
2020's1 (3.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.11 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index5.18 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (7.69%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (3.85%)4.05%
Observational0 (0.00%)0.25%
Other23 (88.46%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]